Source: International Congress 2015 – Patient health gains related to the economic effectiveness of disease management programmes
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Vojislav Cupurdija (Kragujevac, Republic of Serbia), Vojislav Cupurdija, Zorica Lazic, Mihajlo Jakovljevic, Marina Petrovic, Slavica Mojsilovic, Ivan Cekerevac, Ljiljana Novkovic, Romana Susa. Direct costs of treating community-acquired pneumonia do not necessarily correlate with clinical severity. Eur Respir J 2015; 46: Suppl. 59, 1597

Member's Comments

No comment yet.

Related content which might interest you: Does previous warfarin treatment effect complications and outcome in hospitalised patients with community-acquired pneumonia? Source: International Congress 2014 – Different interesting issues in respiratory infections: 2 Year: 2014 Shortening duration of antibiotic therapy according to clinical stability in patients with community-acquired pneumonia (CAP) Source: International Congress 2014 – Respiratory infections: inflammation and treatment Year: 2014 Comparison of severity scores to predict outcomes in elderly patients with community acquired pneumonia Source: International Congress 2015 – CAP: prognostic factors in frail patients Year: 2015 Relationship between the use of inhaled steroids and early outcomes in community-acquired pneumonia Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment Year: 2016 Clinical and laboratory predictors of survival in patients with severe community-acquired pneumonia (CAP) Source: International Congress 2014 – Healthcare, prevention and adjunctive treatments in respiratory infections Year: 2014 Whether there are pharmacoeconomic and other advantages of using procalcitonin-guide antibacterial treatment in patients with severe community-acquired pneumonia in developing countries? Source: International Congress 2015 – Pneumonia: determinants of clinical outcomes and potential strategies to improve its management Year: 2015 Modern etiology of severe community-acquired pneumonia Source: International Congress 2016 – Community-acquired pneumonia: risk classes and management issues Year: 2016 Steroids are not associated with an improvement in clinical outcomes in hospitalized patients with community-acquired pneumonia (CAP) Source: Annual Congress 2009 - Treatment and prevention of lower respiratory tract infections Year: 2009 Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia Source: Annual Congress 2013 –Biomarkers, diagnosis and outcome of respiratory infections Year: 2013 Clinical stability and switch therapy in hospitalised patients with community-acquired pneumonia: are we there yet? Source: Eur Respir J 2013; 41: 5-6 Year: 2013 Clinical factors associated with delayed diagnosis in hospitalized community-acquired pneumonia (CAP). Impact on the outcome Source: Annual Congress 2010 - Risk factors and outcomes in community-acquired pneumonia Year: 2010 Comparison of the predictive performance of severity assessment tools in community-acquired or health care-associated pneumonia Source: Annual Congress 2013 –Manifestations, scores and prognosis of community-acquired pneumonia Year: 2013 Role of procalcitonin in predicting severity and in-hospital mortality in patients with community-acquired pneumonia Source: International Congress 2016 – Community-acquired pneumonia: risk classes and management issues Year: 2016 Features of systemic inflammation in patients with severe community-acquired (CAP) pneumonia of different etiology in HIV-infected patients Source: International Congress 2015 – Immunodepression and severe pneumonia Year: 2015 Increasing outpatient treatment of mild community-acquired pneumonia: systematic review and meta-analysis Source: Eur Respir J 2011; 37: 858-864 Year: 2011 Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: A randomized clinical trial Source: International Congress 2015 – Acute critical care: news from the ICU Year: 2015 Comparison of ampicillin-sulbactam/macrolide dual therapy versus fluoroquinolone monotherapy in hospitalized patients with community-acquired pneumonia Source: International Congress 2015 – Clinical issues in CAP: microbiological and radiological determinants Year: 2015 Predictors of treatment failure in patients with bacteremic pneumococcal community-acquired pneumonia Source: Annual Congress 2013 –Pneumonia and sepsis Year: 2013 Clinical judgement on top of CURB65-score in predicting 30 days clinical outcome in patients with community acquired pneumonia (CAP) admitted to the hospital Source: International Congress 2014 – Pathogenesis and mechanisms of respiratory infections Year: 2014 Effects of using the 2007 IDSA/ATS minor criteria to manage severe community-acquired pneumonia Source: Annual Congress 2013 –Recent developments in pneumonia Year: 2013